SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

SINOVAC BIOTECH LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026

$6.47+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: 850.08%

SINOVAC BIOTECH LTD cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Depreciation & Amortization	–	–	–	–	–	–	–	–	–	–	–	–	–	4.49	4.83	4.23	2.24
Stock-Based Compensation	0	0	0	0	7.74	10	3.00	4.31	0.98	2.41	0.95	0.29	0.28	0.35	0.21	0.46	0.42
Deferred Income Taxes	-90	-56	-17	-84	508	-11	-5.69	3.15	-4.92	-1.01	-0.33	-0.23	-2.23	-0.02	2.85	-1.71	1.26
Change in Accounts Receivable	24	88	41	390	-677	-128	-40	-13	-13	-15	0.04	-9.69	-7.26	-4.29	5.48	1.00	-5.02
Change in Inventory	-23	-0.67	-15	27	-325	-78	-3.65	-9.41	-5.53	-3.03	0.03	-6.13	-7.16	-0.43	-1.92	-8.60	-5.38
Change in Accounts Payable	–	–	109	-87	721	132	6.79	-6.17	33	2.74	-0.30	-3.49	4.45	-0.97	1.21	-0.69	5.12
Change in Unearned Revenue	-1.46	-14	2.23	-50	-289	339	2.52	-0.89	–	–	–	–	–	–	–	–	–
Operating Cash Flow	-512	-57	139	-798	15,322	479	39	7.94	60	-14	4.21	-10	5.58	-16	14	-14	48
Capital Expenditures	-49	-96	-156	-314	-594	0	-11	-5.61	-12	-13	-5.30	-11	-5.13	-16	-15	-25	-4.32
Acquisitions	-14	-100	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Sale of Property, Plant & Equipment	0.41	0.16	0.05	0.61	0.17	0.02	0.02	0.02	0.02	0.03	0.08	0	0	0.01	0.12	0.23	–
Divestitures	–	–	–	–	–	–	–	–	1.71	1.71	0.78	–	–	–	–	–	–
Purchase of Investments	-6,224	-4,912	-5,052	-25,565	-15,840	-403	-51	-20	0	–	–	–	–	–	–	-1.48	-7.31
Sale & Maturity of Investments	10,673	5,595	2,514	19,711	4,744	125	–	–	–	–	–	–	–	–	1.55	7.31	–
Other Investing Activities	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.47	-0.56	–
Investing Cash Flow	4,388	456	-2,699	-6,094	-2,975	-205	-42	-25	-12	-12	-4.52	-11	-5.18	-16	-14	-19	-12
Dividends Paid	-3,534	-947	-328	-247	-1,876	0	0	–	–	–	–	–	–	-0.80	-5.86	-3.29	-3.85
Share Repurchases	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.34
Stock Issued	0	0	0.68	0	1.03	2.00	0	85	1.26	0.32	0.73	0.51	0.81	0.51	0.75	62	0.70
Debt Issued	318	205	243	0.15	13	33	2.11	19	29	45	21	18	17	17	11	20	18
Debt Repaid	-219	-82	-0.31	-63	-45	-6.04	-3.31	-44	-39	-25	-47	-16	-4.09	-4.76	-11	-18	-10
Financing Cash Flow	-3,435	-824	-89	-300	-1,913	593	1.74	64	-1.34	28	-24	5.31	14	17	0.61	58	5.29
Foreign Exchange Rate Adjustments	113	-102	-109	-541	136	27	-0.65	-4.66	4.01	-2.27	-1.54	-1.40	–	–	–	–	–
Net Change in Cash	554	-527	-2,758	-7,733	10,570	894	-2.29	42	51	-0.16	-26	-17	15	-13	2.70	27	–
Free Cash Flow	-561	-153	-18	-1,112	14,728	479	28	2.33	48	-27	-1.09	-21	0.44	-32	-1.52	-39	44
Income Taxes Paid	186	47	-59	1,298	1,486	11	7.31	19	7.91	1.89	2.06	0.49	0	2.27	0.88	5.99	3.07
Interest Paid	9.69	5.80	4.59	1.11	2.61	1.04	0.72	1.49	1.33	1.66	1.72	3.15	2.85	0.75	0.46	1.02	0.91

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 67.9%
Operating margin: -127.0%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 4.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 31.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: 850.08%